The Adverse Events Rate of Endothelial Progenitor Cell Capturing Stent in the Treatment of CAD Patients

Author(s): Wei-Yuan Xu, Wei-Liang Tang, Min Yuan, Yong Sun, Feng Xu, Fang Peng*.

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 21 , Issue 10 , 2018

Become EABM
Become Reviewer

Abstract:

Background: Circulating endothelial progenitor cells (EPCs) have regenerative capacities and play an important role in vessel wall homeostasis. When attracted to the site of vessel wall injury, EPCs rapidly differentiate into a functional layer as part of the healing process. The Genous TM endothelial progenitor cell (EPC) capturing stent is coated with anti-human CD34+ antibodies which combine with circulating EPCs from the peripheral blood to the stent surface.

Objective: This meta-analysis aims to explore the Genous TM endothelial progenitor cell capturing stent in coronary artery disease (CAD) adverse event rate after one-year follow-up.

Methods: PubMed, EMBASE and, Google Scholar databases were searched for eligible studies. CAD survival data and clinicopathological features were analyzed by expected shortfall (ES) and 95% CI. Fixed-effect model and random-effect model are used for summary statistics.

Results: 12 studies, including 15985 coronary artery disease (CAD) patients who received PCI treatment were included in this study. After 1-year follow-up, the rate of adverse event showed that the target vessel failure (TVF) was 8.5% (7.6%-17.4%), target vessel revascularization was 4.1% (TVR, 0-15.6%), target lesion revascularization was 4.2% (TLR, 3.7%-22%), myocardial infarction was 2.0% (MI, 1.8%-5.2%), major adverse cardiac events was 8.7% (MACE, 6.4%-28%), and the all-cause death was 4.0% (0-9.2).

Conclusion: After one-year follow-up, the incidence rate of Genous stent adverse events was stable in CAD patients. The study showed a better evaluation of Genous stent, and it provides a better reference for CAD clinical treatment.

Keywords: Stent, Genous, drug-eluting, restenosis, percutaneous coronary intervention, coronary artery disease.

[1]
Yazdani, S.K.; Nakano, M.; Otsuka, F.; Kolodgie, F.D.; Virmani, R. Accelerating endothelialization of coronary stents by capturing circulating endothelial progenitor cells. Int. Cardiol, 2012, 4(2), 169-181.
[2]
Motwani, M.S.; Rafiei, Y.; Tzifa, A.; Seifalian, A.M. In situ endothelialization of intravascular stents from progenitor stem cells coated with nanocomposite and functionalized biomolecules. Biotechnol. Appl. Biochem., 2011, 58(1), 2-13.
[3]
Padfield, G.J.; Newby, D.E.; Mills, N.L. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J. Am. Coll. Cardiol., 2010, 55(15), 1553-1565.
[4]
Aoki, J.; Serruys, P.W.; van Beusekom, H.; Ong, A.T.; McFadden, E.P.; Sianos, G.; van der Giessen, W.J.; Regar, E.; de Feyter, P.J.; Davis, H.R.; Rowland, S.; Kutryk, M.J. Endothelial progenitor cell capture by stents coated with antibody against cd34: The healing-fim (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J. Am. Coll. Cardiol., 2005, 45(10), 1574.
[5]
Duckers, H.J.; Soullié, T.; den Heijer, P.; Rensing, B.; de Winter, R.J.; Rau, M.; Mudra, H.; Silber, S.; Benit, E.; Verheye, S.; Wijns, W.; Serruys, P.W. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: Final results of the healing ii trial using an endothelial progenitor cell. EuroIntervention, 2007, 3(3), 350.
[6]
Tan, A.; Goh, D.; Farhatnia, Y.G.N.; Lim, J.; Teoh, S.H.; Rajadas, J.; Alavijeh, M.S.; Seifalian, A.M. An anti-cd34 antibody-functionalized clinical-grade poss-pcu nanocomposite polymer for cardiovascular stent coating applications: A preliminary assessment of endothelial progenitor cell capture and hemocompatibility. PLoS One, 2013, 8(10), e77112.
[7]
Beijk, M.A.; Damman, P.; Klomp, M.; Woudstra, P.; Silber, S.; Grisold, M.; Ribeiro, E.E.; Suryapranata, H.; Wójcik, J.; Sim, K.H.; Tijssen, J.G.; de Winter, A.R. e-HEALING investigators. Twelve-month clinical outcomes after coronary stenting with the genous bio-engineered r stent in patients with a bifurcation lesion: From the e-healing (healthy endothelial accelerated lining inhibits neointimal growth) registry. Coron. Artery Dis., 2012, 23(3), 201-207.
[8]
Klomp, M.; Damman, P.; Beijk, M.A.; Silber, S.; Grisold, M.; Ribeiro, E.E.; Suryapranata, H.; Wòjcik, J.; Sim, K.H.; Tijssen, J.G.; de Winter, R.J. e-HEALING investigators. Applying the national institute for clinical excellence criteria to patients treated with the genous™ bio-engineered r stent™: A sub-study of the e-healing (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry. Heart Vessels, 2012, 27(4), 360-369.
[9]
Azzarelli, S.; Galassi, A.R.; Grosso, G.; Tomasello, D.; Campisano, B.; Giacoppo, M.; Argentino, V.; Amico, F.; Fiscella, A. Clinical and angiographic outcomes in elderly patients treated with endothelial progenitor cell capture coronary stents: Results from a prospective single-center registry. J. Invasive Cardiol., 2010, 22(12), 594.
[10]
Pereira-Da-Silva, T.; Bernardes, L.; Cacela, D.; Fiarresga, A.; Sousa, L.; Patrício, L.; Ferreira, R.C. Safety and effectiveness of the genous™ endothelial progenitor cell-capture stent in the first year following st-elevation acute myocardial infarction: A single center experience and review of the literature. Cardiovasc. Revasc. Med., 2013, 14(6), 338.
[11]
Lee, Y.P.; Tay, E.; Lee, C.H.; Low, A.; Teo, S.G.; Poh, K.K.; Yeo, W.T.; Lim, J.; Lim, I.H.; Lim, Y.T.; Tan, H.C. Endothelial progenitor cell capture stent implantation in patients with st-segment elevation acute myocardial infarction: One year follow-up. EuroIntervention, 2010, 5(6), 698.
[12]
Co, M.; Tay, E.; Lee, C.H.; Poh, K.K.; Low, A. Lim.; Lim, I.H.; Lim, Y.T.; Tan, H.C. Use of endothelial progenitor cell capture stent (genous bio-engineered r stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up. Am. Heart J., 2008, 155(1), 128.
[13]
Damman, P.; Iñiguez, A.; Klomp, M.; Beijk, M.; Woudstra, P.; Silber, S.; Ribeiro, E.E.; Suryapranata, H.; Sim, K.H.; Tijssen, J.G.; de Winter, R.J. e-HEALING investigators. Coronary stenting with the genous™ bio-engineered r stent™ in elderly patients. Circ. J., 2011, 75(11), 2590-2597.
[14]
den Dekker, W.K.; Houtgraaf, J.H.; Onuma, Y.; Benit, E.; de Winter, R.J.; Wijns, W.; Grisold, M.; Verheye, S.; Silber, S.; Teiger, E.; Rowland, S.M.; Ligtenberg, E.; Hill, J.; Wiemer, M.; den Heijer, P.; Rensing, B.J.; Channon, K.M.; Serruys, P.W.; Duckers, H.J. Final results of the healing iib trial to evaluate a bio-engineered cd34 antibody coated stent (genous™stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in cad patients. Atherosclerosis, 2011, 219(1), 245-252.
[15]
Silber, S.; Damman, P.; Klomp, M.; Beijk, M.A.; Grisold, M.; Ribeiro, E.E.; Suryapranata, H.; Wójcik, J.; Hian Sim, K.; Tijssen, J.G.; de Winter, R.J. Clinical results after coronary stenting with the genous™ bio-engineered r stent™: 12-month outcomes of the e-healing (healthy endothelial accelerated lining inhibits neointimal growth) worldwide registry. EuroIntervention, 2011, 6(7), 819-825.
[16]
Beijk, M.A.; Klomp, M.; Verouden, N.J.; van Geloven, N.; Koch, K.T.; Henriques, J.P.; Baan, J.; Vis, M.M.; Scheunhage, E.; Piek, J.J.; Tijssen, J.G.; de Winter, R.J. Genous™ endothelial progenitor cell capturing stent vs. The taxus liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: A randomized, single-centre, pilot study. Eur. Heart J., 2010, 31(9), 1055-1064.
[17]
Klomp, M.; Beijk, M.A.; Varma, C.; Koolen, J.J.; Teiger, E.; Richardt, G.; Bea, F.; van Geloven, N.; Verouden, N.J.; Chan, Y.K.; Woudstra, P.; Damman, P. Tijssen J.G.; de Winter, R.J. 1-year outcome of trias hr (tri-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc. Interv., 2011, 4(8), 896.
[18]
Beijk, M.A.; Klomp, M.; Koch, K.T.; Henriques, J.P.; Vis, M.M.; Baan, J., Jr; Tijssen, J.G.; Piek, J.J.; de Winter, R.J. One-year clinical outcome after provisional t-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. Atherosclerosis, 2010, 213(2), 525-531.
[19]
Moses, J.W.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.J. Holmes, D.R.; O’Shaughnessy, C.; Caputo, R.P.; Kereiakes, D.J.; Williams, D.O.; Teirstein, P.S.; Jaeger, J.L.; Kuntz, R.E.; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med., 2003, 349(14), 1315-1323.
[20]
Stone, G.W.R.; Bergin, P.; Greenberg, J.; Popma, J.J.; Russell, M.E. TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med., 2004, 350(3), 221-231.
[21]
Yang, X.S.; Zhu, H.G.; Yu, Z.J.; Ren, F.; Chen, Y.Q.; Wu, X.; Zhang, Z.C.; Zhang, L.J.; Lu, S.Z. The union of anti-cd34 antibody can offset the inhibitory effect of sirolimous-eluting stents on the re-endothelialization. Catheter. Cardiovasc. Interv., 2012, 79(6), 972-978.
[22]
Farb, A.; Boam, A.B. Stent thrombosis redux—the fda perspective. N. Engl. J. Med., 2007, 356(10), 984-987.
[23]
Daemen, J.; Wenaweser, P.; Tsuchida, K.; Abrecht, L.; Vaina, S.; Morger, C.; Kukreja, N.; Jüni, P.; Sianos, G.; Hellige, G.; van Domburg, R.T.; Hess, O.M.; Boersma, E.; Meier, B.; Windecker, S.; Serruys, P.W. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet, 2007, 369(9562), 667-678.
[24]
Asahara, T.; Masuda, H.; Takahashi, T.; Kalka, C.; Pastore, C.; Silver, M.; Kearne, M.; Magner, M.; Isner, J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res., 1999, 85(3), 221-228.
[25]
Sprague, E.A.; Tio, F.; Ahmed, S.H.; Granada, J.F.; Bailey, S.R. Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation, and function: An in vivo correlation study of the healing response in the coronary swine model. Circ. Cardiovasc. Interv., 2012, 5(4), 499-507.
[26]
Yang, F.; Feng, S.C.; Pang, X.J.; Li, W.X.; Bi, Y.H.; Zhao, Q.; Zhang, S.X.; Wang, Y.; Feng, B. Combination coating of chitosan and anti-cd34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation. BMC Cardiovasc. Disord., 2012, 12(1), 96.
[27]
Ohlden, A. Multiple clinical data presentations at europcr 2008 support use of orbusneich's genous(tm) bio-engineered r stent(tm) as safe alternative to Drug - Eluting Stents. (May 15 2008).
[28]
Kutryk, M.; Kuliszewski, M. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am. J. Cardiol., 2003, 92, 941.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 10
Year: 2018
Page: [725 - 733]
Pages: 9
DOI: 10.2174/1386207322666190129113448
Price: $58

Article Metrics

PDF: 26
HTML: 5
EPUB: 1

Special-new-year-discount